Carboplatin in patients with advanced colorectal cancer pretreated with fluoropyrimidines
- 31 December 1993
- journal article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 29 (9), 1330-1331
- https://doi.org/10.1016/0959-8049(93)90085-t
Abstract
The activity of carboplatin (CBDCA) was tested in 21 consecutive patients with advanced colorectal cancer that had progressed during fluoropyrimidine therapy. CBDCA was chosen in view of the favourable results obtained in previous phase II studies. We were unable to find any activity of the agent which was given every 21 days at a dose of 400 mg/m2. The main toxicity was haematological. CBDCA is not recommended in pretreated patients with colorectal cancer.Keywords
This publication has 5 references indexed in Scilit:
- A Phase II Study of Carboplatin and CHIP in Patients with Metastatic Colon CarcinomaAmerican Journal of Clinical Oncology, 1989
- CBDCAAmerican Journal of Clinical Oncology, 1987
- Combination Chemotherapy for Advanced Colorectal Cancer A Pilot StudyAmerican Journal of Clinical Oncology, 1986
- Chemotherapy of Gastrointestinal CancerNew England Journal of Medicine, 1978
- Inhibitory effects of anti‐tumor platinum compounds on DNA, RNA and protein syntheses in mammalian cells in vitroInternational Journal of Cancer, 1970